BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the feasibility of combining pembrolizumab with a
single fraction radiation boost in patients with early/operable breast cancer. The secondary
objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and
histology exams, and to assess immune response on pre and post treatment blood and tissue
samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor
infiltrating lymphocytes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania University of Pennsylvania